|
| |
BPI Announces First Sales of Next-Generation TISSUEscope ™
The first automated panoramic imaging system to provide both brightfield and
fluorescence virtual slides in 3-D without tiling
Waterloo, ON, March 30, 2007: Biomedical Photometrics Inc. (BPI)
announces today sales and shipments of the next-generation TISSUEscope™ to early
customers, marking the first official placements of the new instrument. The
first customers of BPI’s next-generation TISSUEscope™, to be launched broadly
later this year, include the Sunnybrook Health Sciences Center (SHSC) in
Toronto, Canada and the Robarts Research Institute (RRI) in London, Canada.
The sales follow continuing collaborations with these and other leading
healthcare, imaging and pharma research organizations. SHSC, previously
announced as the independent test site for the first TISSUEscope™ prototype,
completed the purchase of an Alpha instrument in February 2006 and have now
purchased and received a second unit. Field testing of TISSUEscope™ Beta
instruments commenced in June 2006 in conjunction with organizations in the US
and Canada, including both RRI and SHSC. 10-15X speed-up in throughput over
existing digitization methods was achieved during field testing of the
TISSUEscope™ at RRI in vascular, pulmonary and oncology applications.
The TISSUEscope™ uses BPI’s patented panoramic MACROscope® technology to produce
a high-resolution digital image of the entire tissue specimen in a single scan
without the time consuming process of tiling 1000’s of images. The resulting
virtual slide is stored in a single digital file, enabling low and
high-resolution images of the entire tissue specimen to be easily displayed,
manipulated, distributed and interpreted. In addition to brightfield imaging,
the TISSUEscope™ has the high sensitivity necessary to simultaneously view
tissue specimens using several other contrast mechanisms including fluorescence.
Fluorescence is a growing requirement for advanced quantitative molecular
imaging needed by research pathologists for detecting cancers and monitoring
treatment. Specimen images that require multiple contrast mechanisms that may
take hours to produce with image tiling processes can now be done with the
TISSUEscope™ in minutes. Further, the confocal characteristic of the TISSUEscope™
also allows for optical sectioning and construction of 3-D virtual slides.
No other virtual microscopy imaging technology combines simultaneous acquisition
and manipulation of registered brightfield and fluorescence images, panoramic
field-of-view (more than 100 times that of a standard microscope on an area
basis), the ability to capture the entire image in a single scan, and confocal
imaging capability in one instrument. Complete specifications for products can
be found at www.confocal.com.
About Biomedical Photometrics Inc.
Founded in 1994, Biomedical Photometrics Inc. (BPI) develops, manufactures and
markets automated, fluorescence scanning laser imaging systems that combine
patented panoramic confocal technology with microscope functionality. BPI
Products are used around the world by leading pharmaceutical, government,
academic and medical research organizations to gain new insight for better
decision making into such varied applications as tissue regeneration, efficacy
of experimental drugs on specific cell signaling pathways in tumors,
toxicological changes in neuronal cell populations, 3D histology for new imaging
modality validation, custom microarray development, and dynamic scanning of
integrated fluidic circuits (IFCs).
Contact:
Glenn Smith
Biomedical Photometrics Inc.
Phone: (519) 886-9013 x38
Email: gsmith@confocal.com
Fax: (519) 886-5300
| |
|
